@rangelgomez

Are some GLP-1 medicines more cardioprotective than others? #easd25 A new real world study using US Medicare data https://t.co/dh0F8R573g

#NuevaFotoDePerfil

2️⃣ Diseño del estudio SURPASS-CVOT compara tirzepatida vs dulaglutida 1.5 mg QW en DM2+ASCVD. Escalada progresiva de tirzepatida hasta 15 mg. Seguimiento mediano 4 años. Endpoint primario: MACE. Diseño robusto y pragmático. #Endocrinología #EASD25

#EASD25 highlights. Modern GLP-1 medicines such as tirzepatide are cardioprotective, can/should be tested using ethical trial designs and the dose response for metabolic endpoints does not perfectly mirror that for reduction of MACE #CVD #T2D

“We must not make the mistake and think low-carb diets mean no carbs” - Professor Nita Gandhi Forouhi #easd25

Excited to know the results of the SURPASS-CVOT trial. When you are a researcher in a study, the excitement is even greater. #EASD25

Have a seat, join the conversation, and see how lived experience is transforming diabetes care across professional & systemic levels. 📅 Thu, 18 Sep | 🕒 15:30–17:00 CEST 📍 Cairo Hall, VIECON Vienna #dedocº #EASD2025 #Diabetes #NothingAboutUsWithoutUs #EASD25 #symposium

❤️ Guten abend Wien 🇦🇹 Day4 #easd25 ✨️👌🏻 #team #Aberdeen | @aberdeenuni ❤️| @AberdeenCDC 🧡| @mdelibeg 💛| @EpitogenX 💜| @ktpnorthscot 💚 #T1D #serology 🩸#diagnostics 🧪#powerofpurple 💜 #nothinghidesfromthescaffold #Innovation 💡 #biotechnology

UCDC researchers presented their latest work on an international stage at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria, Sept. 15-19. Read more: https://t.co/LGH946qQD7 #EASD25 #T1diabetes

1️⃣ Baseline characteristics En SURPASS-CVOT los pacientes con DM2 y ASCVD presentaban alta carga de riesgo: 65% enfermedad coronaria, 47% IAM previo, IMC medio 32.6 kg/m², HbA1c 8.4%. Cohorte muy representativa del escenario clínico real. #Diabetes #cardiovasculardisease #EASD25

Cardiovascular-Diabetes-obesity-health plan. ¿Somos conscientes o consecuentes en nuestra práctica diaria de esta necesidad/realidad? Independizar patologías o pacientes: NO. #EASD25 #diabetes #obesidad

#NEWS: #VTV today announced its participation at the INNODIA Symposium at @EASDnews’s #EASD25 meeting where our EVP & CSO Carmen Valcarce, Ph.D., will conduct a presentation, underscoring vTv’s commitment to improving the lives of people w/ diabetes. https://t.co/6HN94uttrd #VTVT

EMJ are at #EASD25! From groundbreaking research to cutting-edge clinical trial results and expert debates, the team will be following the key discussions shaping the future of diabetes research and care. Subscribe to EMJ Diabetes to find out more: https://t.co/dZb95a0Ds4

Thrilled to share our latest publication in @NEJM ,the ATTAIN-1 trial, the first phase 3 study of oral orforglipron in people living with obesity. We will be presenting the results today at #EASD25 — an important milestone in advancing obesity care. https://t.co/tcFoQgufBM

EMJ are at #EASD25! From groundbreaking research to cutting-edge clinical trial results and expert debates, the team will be following the key discussions shaping the future of diabetes research and care. Subscribe to EMJ Diabetes to find out more: https://t.co/eJnhvK0NBb

@easd25 ¡Gracias por participar! Sigue apoyando en #CopaAmericaDIRECTVVenezuela ¡Acompaña a la Vinotinto! http://t.co/trglDHymjD

Among many highlights today #easd25 @EASDnews The @novonordiskfond Prize lecture

Catch up on the latest breakthroughs in #diabetes research from #EASD25 with our congress hub. Access for free 👉 https://t.co/GRoiqxrPqe #MedNews